Top

Published in:

01-10-2014 | Brief Report

Predictors of Medication Non-adherence in Bulgarian Outpatients with Schizophrenia

Authors: Iglika Vassileva, Vihra Milanova, Turan Asan

Published in: Community Mental Health Journal | Issue 7/2014

Abstract

The purpose of this study is to assess the adherence status and to identify the risk factors for medication non-adherence in Bulgarian outpatients with schizophrenia. Variables with possible impact on adherence behaviour were assessed via a set of pre-determined clinical interviews and self-rating scales in a total of 226 patients with schizophrenia. As non-adherent were classified 55.8 % of the participants. Differences between adherent and non-adherent patients were identified. A multiple regression analysis revealed three variables predictive for the medication adherence—attitudes toward medication, severity of positive symptoms and the ability to recognize psychotic symptoms. Interventions focusing on the identified predictive variables might be useful when aiming at improvement of medication adherence and outcome in schizophrenia.

Alia-Klein, N., O’Rourke, T., Goldstein, R., & Malaspina, D. (2007). Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggressive Behavior, 33, 86–96.PubMedCrossRef

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text Revision, p. 34). Washington, DC: American Psychiatric Association.

Ascher-Svanum, H., Faries, D., Zhu, B., Ernst, F. R., Swartz, M. S., & Swanson, J. (2006a). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry, 67, 453–460.PubMedCrossRef

Ascher-Svanum, H., Zhu, B., Faries, D., Lacro, J., & Dolder, C. (2006b). A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. Journal of Clinical Psychiatry, 67, 1114–1123.PubMedCrossRef

Ascher-Svanum, H., Zhu, B., Faries, D., Lacro, J., Dolder, C., & Peng, X. (2008). Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence, 2, 67–77.PubMedPubMedCentralCrossRef

Brnabic, A., Kelin, K., Ascher-Svanum, H., Montgomery, W., Kadziola, Z., & Karagianis, J. (2011). Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. International Journal of Clinical Practice, 65(9), 945–953.PubMedCrossRef

Buckley, P., Wirshing, D., Bhushan, P., Pierre, J., Resnick, S., & Wirshing, W. (2007). Lack of insight in schizophrenia: Impact on treatment adherence. CNS Drugs, 21(2), 129–141.PubMedCrossRef

David, A. (1990). Insight and psychosis. British Journal of Psychiatry, 156, 798–808.PubMedCrossRef

David, A., Buchanan, A., Reed, A., & Almeida, O. (1992). The assessment of insight in psychosis. British Journal of Psychiatry, 161, 599–602.PubMedCrossRef

Day, J., Wood, G., Dewey, M., & Bentall, R. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. The British Journal of Psychiatry, 166, 650–653.PubMedCrossRef

Diaz, E., Woods, S., & Rosenheck, R. (2005). Effects of ethnicity on psychotropic medications adherence. Community Mental Health Journal, 41, 521–537.PubMedCrossRef

Dingemans, P., Linszen, D., Lenior, M., & Smeets, R. (1995). Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology (Berl), 122(3), 263–267.CrossRef

Dolder, C., Lacro, J., Dunn, L., & Jeste, D. (2002). Antipsychotic medication adherence: Is there a difference between typical and atypical agents? American Journal of Psychiatry, 159, 103–108.PubMedCrossRef

Dolder, C., Lacro, J., Leckband, S., & Jeste, D. (2003). Interventions to improve antipsychotic medication adherence: Review of recent literature. Journal of Clinical Psychopharmacology, 23(4), 389–399.PubMedCrossRef

Fenton, W., Biller, C., & Heinssen, R. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23, 637–651.PubMedCrossRef

Freudenreich, O., & Cather, C. (2012). Antipsychotic medication nonadherence: Risk factors and remedies. Focus, 10, 124–129.

Garcia-Ribera, C., & Bulbena, A. (2011). Determinants of medicine-taking in psychiatric patients. Current Clinical Pharmacology, 6(2), 100–107.PubMedCrossRef

Gilmer, T., Dolder, C., Lacro, J., Folsom, D., Lindamer, L., Garcia, P., et al. (2004). Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. American Journal of Psychiatry, 161(4), 692–699.PubMedCrossRef

Hogan, T., Awad, A., & Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine, 13(1), 177–183.PubMedCrossRef

Jeste, S., Patterson, T., Palmer, B., Dolder, C., Goldman, S., & Jeste, D. (2003). Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophrenia Research, 63, 49–58.PubMedCrossRef

Kim, S.-W., Yoon, J.-S., & Choi, S.-K. (2006). Survey of medication adherence in patients with schizophrenia—Korean ADHES data. Human Psychopharmacology: Clinical and Experimental, 21, 533–537.CrossRef

Klingberg, S., Schneider, S., Wittorf, A., Buchkremer, G., & Wiedemann, G. (2008). Collaboration in outpatient antipsychotic drug treatment: Analysis of potentially influencing factors. Psychiatry Research, 161, 225–234.PubMedCrossRef

Lacro, J., Dunn, L., Dolder, C., Leckband, S., & Jeste, D. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892–909.PubMedCrossRef

Lambert, M., Conus, P., Eide, P., Mass, R., Karrow, A., Moritz, S., et al. (2004). Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. European Psychiatry: The Journal of the Association of European Psychiatrists, 19(7), 415–422.CrossRef

Law, M., Soumerai, S., Ross-Degnan, D., & Adams, A. (2008). A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. Journal of Clinical Psychiatry, 69, 47–53.PubMedCrossRef

Leucht, C., Heres, S., Kane, J., Kissling, W., Davis, J., & Leucht, S. (2011). Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research, 127(1–3), 83–92.PubMedCrossRef

Lieberman, J., Stroup, T., McEvoy, J., Swartz, M., Rosenheck, R., Perkins, D., et al. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353, 1209–1223.PubMedCrossRef

Lincoln, T., Lüllmann, E., & Rief, W. (2007). Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophrenia Bulletin, 33(6), 1324–1342.PubMedPubMedCentralCrossRef

Lucoff, D., Nuechterlein, K., & Ventura, J. (1986). Manual for the expanded brief psychiatric rating scale. Schizophrenia Bulletin, 12, 594–602.

Masand, P., & Narasimhan, M. (2006). Improving adherence to antipsychotic pharmacotherapy. Current Clinical Pharmacology, 1, 47–56.PubMedCrossRef

Masand, P., Roca, M., Turner, M., & Kane, J. (2006). Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. The Primary Care Companion to the Journal of Clinical Psychiatry, 11(4), 147–154.CrossRef

McCabe, R., Bullenkamp, J., Hansson, L., Lauber, C., Martinez-Leal, R., Rössler, W., et al. (2012). The therapeutic relationship and adherence to antypsychotic medication in schizophrenia. PLoS ONE, 7(4), e36080. doi:10.1371/journal.pone.0036080.PubMedPubMedCentralCrossRef

McCombs, J., Nichol, M., Stimmel, G., Shi, J., & Smith, R. (1999). Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. Journal of Clinical Psychiatry, 60(19), 5–11.PubMed

Menzin, J., Boulanger, L., Friedman, M., Mackell, J., & Lloyd, J. (2003). Treatment adherence associated with conventional and atypical antipsychotics in a large State Medicaid program. Psychiatric Services, 54(5), 719–723.PubMedCrossRef

Mitchell, A., & Selmes, T. (2007). Why don’t patients take their medicine? Reasons and solutions in psychiatry. Advances in Psychiatric Treatment, 13, 336–346.CrossRef

Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., & Lieberman, J. (2009). Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin, 35(2), 336–346.PubMedPubMedCentralCrossRef

Morisky, D., Green, L., & Levine, D. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24, 67–74.PubMedCrossRef

Mutsatsa, S., Joyce, E., Hutton, S., Webb, E., Gibbins, H., et al. (2003). Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandinavica, 108(6), 439–446.PubMedCrossRef

Naber, D., Karow, A., & Lambert, M. (2005). Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica Supplement, 427, 29–34.CrossRef

Nielsen R., Lindström E., Nielsen J., & Levander S. (2012). DAI-10 is as good as DAI-30 in schizophrenia. European Neuropsychopharmacology. doi:10.1016/j.euroneuro.2012.02.008.

Nosé, M., Barbui, C., & Tansella, M. (2003). How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine, 33, 1149–1160.PubMedCrossRef

Novick, D., Haro, J., Suarez, D., Perez, V., Dittmann, R., & Haddad, P. (2010). Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research, 176(2–3), 109–113.PubMedCrossRef

Olivares, J., Pinal, B., & Cinos, C. (2011). Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. Neuropsychiatry, 1(3), 275–289.CrossRef

Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353, 487–497.PubMedCrossRef

Patel, M., Zoysa, N., Bernadt, M., & David, A. (2008). A cross-sectional study patients’ perspectives on adherence to antipsychotic medication: Depot versus oral. Journal of Clinical Psychiatry, 69, 1548–1556.PubMedCrossRef

Perkins, D. (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63, 1121–1128.PubMedCrossRef

Pompilli, M., Lester, D., Grispini, A., Innamorati, M., Calandro, F., Iliceto, P., et al. (2009). Completed suicide in schizophrenia: Evidence from a case-control study. Psychiatry Research, 167(3), 251–257.CrossRef

Priebe, S., & Gruyters, T. (1993). The role of the helping alliance in psychiatric community care. A prospective study. Journal of Nervous and Mental Disease, 181, 552–557.PubMedCrossRef

Priebe, S., & Gruyters, T. (1995). Assessment of treatment predicting outcome. Schizophrenia Bulletin, 21(1), 87–94.PubMedCrossRef

Priebe, S., Huxley, P., Knight, S., & Evans, S. (1999). Application and results of the Manchester Short Assessment of Quality of Life (Mansa). International Journal of Social Psychiatry, 45(1), 7–12.PubMedCrossRef

Puschner, B., Born, A., Giebler, A., Helm, H., Leese, M., Bindman, J., et al. (2006). Adherence to medication and quality of life in people with schizophrenia. Journal of Nervous and Mental Diseases, 194, 746–752.CrossRef

Roy, A., & Pompili, M. (2009). Management of schizophrenia with suicide risk. Psychiatric Clinics of North America, 32, 863–883.PubMedCrossRef

Rummel-Kluge, C., Schuster, T., Peters, S., & Kissling, W. (2008). Partial compliance with antipsychotic medication is common in patients with schizophrenia. Australian and New Zealand Journal of Psychiatry, 42(5), 382–388.PubMedCrossRef

Sellwood, W., Tarrier, N., Quinn, J., & Barrowclough, C. (2003). The family and compliance in schizophrenia: The influence of clinical variables, relatives’ knowledge and expressed emotion. Psychological Medicine, 33(1), 91–96.PubMedCrossRef

Sun, S., Liu, G., Christensen, D., & Fu, A. (2007). Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Current Medical Research and Opinion, 23, 2305–2312.PubMedCrossRef

Tsang, H., Fung, K., & Corrigan, P. (2009). Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia. Journal of Behavior Therapy and Experimental Psychiatry, 40(1), 3–14.PubMedCrossRef

Valenstein, M., Blow, F., Copeland, L., McCarthy, J., Zeber, J., Gillon, L., et al. (2004). Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophrenia Bulletin, 30, 255–264.PubMedCrossRef

Valenstein, M., Ganoszy, D., McCarthy, J. F., Myra, K. H., Lee, T., & Blow, F. (2006). Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review. Journal of Clinical Psychiatry, 67(10), 1542–1550.PubMedCrossRef

Velligan, D., Weiden, P., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., et al. (2009). The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry, 70, S4.

Ventura, J., Green, M., Shaner, A., & Liberman, R. (1993). Training and quality assurance with the Brief Psychiatric Rating Scale: ‘The drift busters’. International Journal of Methods in Psychiatric Research, 3, 221–244.

Wiffen, B. D., Rabinowitz, J., Lex, A., & David, A. S. (2010). Correlates, change and ‘state or trait’ properties of insight in schizophrenia. Schizophrenia Research, 122(1–3), 94–103.PubMedCrossRef

Wilk, J., Marcus, S., West, J., et al. (2006). Substance abuse and the management of medication nonadherence in schizophrenia. Journal of Nervous and Mental Disease, 194, 454–457.PubMedCrossRef

World Health Organization. (2003). Adherence to long term therapy: Evidence for action. http://www.who.int/chronic_conditions/adherencereport/en/.

Yen, C.-F., Chen, C.-S., Ko, Ch-H, Yeh, M., Yang, S., Yen, J., et al. (2005). Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: Prospective study. Psychiatry and Clinical Neurosciences, 59(4), 403–409.PubMedCrossRef

Zygmunt, A., Olfson, M., Boyer, C., & Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry, 159, 1653–1664.PubMedCrossRef

Title: Predictors of Medication Non-adherence in Bulgarian Outpatients with Schizophrenia
Authors: Iglika Vassileva
Vihra Milanova
Turan Asan
Publication date: 01-10-2014
Publisher: Springer US
Published in: Community Mental Health Journal / Issue 7/2014
Print ISSN: 0010-3853
Electronic ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-014-9697-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Predictors of Medication Non-adherence in Bulgarian Outpatients with Schizophrenia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

“I Just Have to Stick with It and It’ll Work”: Experiences of Adolescents and Young Adults with Mental Health Concerns

Homelessness, Behavioral Health Disorders and Intimate Partner Violence: Barriers to Services for Women

Flexibility and Structure May Enhance Implementation of Family-Focused Therapy in Community Mental Health Settings

Religious Participation and Substance Use Behaviors in a Canadian Sample of Homeless People

Cannabis Use is a Better Indicator of Poor Mental Health in Women Than in Men: A Cross-Sectional Study in Young Adults from the General Population

Leadership, Organizational Climate, and Working Alliance in a Children’s Mental Health Service System